No Data
No Data
Express News | The ban on restricted shares with a market capitalization of 10.975 billion yuan was lifted today
About 18.351,400 restricted shares of Rayon Gene (688217.SH) will be listed and distributed from May 17
Rayon Gene (688217.SH) announced that the restricted shares listed and circulated are restricted shares of the company's initial public offering. The limited sale period is 36 months from the date of listing of the company's shares, involving 6 shareholders. The number of restricted shares corresponding to this group of shareholders is approximately 18.3514 million shares, accounting for 32.85% of the company's total share capital. Currently, the sales restriction period for the restricted shares mentioned above is about to expire, and they will be listed and circulated on May 17, 2024.
Rayon Gene (688217.SH): 1.20% of shares have been repurchased cumulatively
Gelonghui, May 7 | Ruiang Gene (688217.SH) announced that as of April 30, 2024, the company had repurchased 669,621 shares of the company through centralized bidding transactions, accounting for 1.20% of the company's total share capital of 55,855,896 shares. The highest price of the repurchase transaction was 27.67 yuan/share, the lowest price was 22.37 yuan/share, and the total amount of capital paid was RMB 17,021,747.99 (excluding transaction fees such as stamp duty and transaction fees).
Rayon Gene (688217.SH): Net profit for the first quarter was 533,200 yuan, down 58.70% year on year
On April 26, Ge Longhui (688217.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 64,1882 million yuan, a year-on-year increase of 12.84%; net profit attributable to shareholders of listed companies was 533,200 yuan, a year-on-year decrease of 58.70%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses - 614,600 yuan; and basic earnings per share.
Rayon Gene (688217): Oncology related core business is growing steadily, deepening applications in the field of accurate tumor diagnosis
Incident: Recently, the company released its 2023 annual report, and revenue declined. In 2023, the company achieved a total revenue of 258 million yuan, a year-on-year decrease of 39.14%; realized net profit to mother of 7.9307 million yuan, the same
Rayon Gene (688217.SH): Net profit of 7.93 million yuan in 2023 fell 80.41% year on year
On April 16, GLONGHUI (688217.SH) released its 2023 annual report, with operating income of 258 million yuan, a year-on-year decrease of 39.14%, net profit of 7.93 million yuan, a year-on-year decrease of 80.41%, after deducting non-net profit of 3.695 million yuan, a year-on-year decrease of 89%, with basic earnings of 0.14 yuan per share.
No Data